Global Cord Blood Corporation (CO) News
Filter CO News Items
CO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CO News From Around the Web
Below are the latest news stories about GLOBAL CORD BLOOD CORP that investors may wish to consider to help them evaluate CO as an investment opportunity.
Global Cord Blood Corporation Files Annual Report on Form 20-FGlobal Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2022. The Form 20-F can be accessed by visiting the U.S. Securities and Exchang |
Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGMGlobal Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order") previously obtained by the Company on June 15, 2022 from the Grand Court of the Cayman Islands (the "Court") against Blue Ocean Structure Investment Company Limited ("Blue Ocean") was officially issued by the Court on July 6, 2022. The Orde |
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022. |
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of MyelofibrosisGlobal Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelof |
Shareholders Led by Blue Ocean Announce Successful Results of Extraordinary General Meeting of Global Cord Blood CorporationNEW YORK, June 16, 2022--Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") and shareholders representing over 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO) today announced the successful approval of all resolutions at the Global Cord Extraordinary General Meeting of Shareholders ("EGM") held today. 104,369,577 shares out of 121,551,075 total outstanding shares of Global Cord voted in the EGM, which represents 85.86 percent o |
Global Cord Blood Corporation Announces Purported EGM Is Not Validly ConvenedGlobal Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that on June 3, 2022 Blue Ocean Structure Investment Company Limited (the "Petitioner") issued a notice which purported to convene an extraordinary general meeting of the Company ("Purported EGM") which is due to be held on June 16, 2022. |
Shareholders of Global Cord Blood Corporation Are Reminded to Comply with the Rules of Conduct When Attending the Extraordinary General Meeting and Exercising Their Voting RightsNEW YORK, June 15, 2022--Blue Ocean Structure Investment Company Ltd.,("Blue Ocean") together with shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO) have called an Extraordinary General Meeting of Shareholders ("EGM" or the "Meeting") as allowed by the Company’s Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 J |
Shareholders Led by Blue Ocean Call Extraordinary General Meeting of Global Cord Blood Corporation Shareholders to Terminate its Proposed Acquisition of Cellenkos, Inc. and Elect New BoardNEW YORK, June 03, 2022--Blue Ocean Structure Investment Company Ltd.,("Blue Ocean") announced today that shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO), have called an Extraordinary General Meeting of Shareholders ("EGM") as allowed by the Company’s Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 June, 2022 |
Blue Ocean Announces Virgin Islands Court Grants Injunction Order Prohibiting Golden Meditech from Taking Any Steps on a Purported Share Charge from Blue Ocean or Pursuing the Removal of Blue Ocean’s Representative as a Director of Global Cord BloodNEW YORK, May 27, 2022--Blue Ocean Structure Investment Company Ltd. ("Blue Ocean"), a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO), today announced that the Eastern Caribbean Supreme Court in the High Court of Justice of the Virgin Islands (the "Court") granted an injunction order ("the Order") enjoining Golden Meditech Stem Cells (BVI) Company Limited ("Golden Meditech") from taking any steps on a purported share charge from Blue Ocean an |
Blue Ocean Comments on Fraudulent Claims from Conflicted Party Golden Meditech Regarding Global Cord Blood CorporationNEW YORK, May 23, 2022--Blue Ocean Structure Investment Company Ltd. ("Blue Ocean"), a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO), today commented on what Blue Ocean believes to be a shocking, distracting and fraudulent Schedule 13D filing made by Golden Meditech Stem Cells (BVI) Company Limited ("Golden Meditech") with the U.S. Securities and Exchange Commission. |